The YELLOW III Study (NCT04710368) demonstrated how 26 weeks of Evolocumab could reduce NIRS mxLCBI (-93.7) and IVUS PAV (-1.38%) in non culprit lesions in stable angina patients. View the study and watch Dr. Annapoorna Kini’s interview at the American College of Cardiology (ACC) 2023 Annual Scientific Sessions.

WATCH INTERVIEW

Clinical Evidence

The evidence is clear. Multiple research studies have shown how NIRS Imaging can help identify lipid core plaque (LCP), an underlying cause of serious cardiac events. Click to download an overview outlining the Prospect II, PACMAN-AMI, and LRP clinical study findings.

PACMAN-AMI Randomized Clinical Trial: Shows Reduced Plaque Regression in AMI Patients Treated with Alirocumab Principal Investigator:Lorenz Räber, MD, PhD View ACC Presentation View JAMA Abstract

PROSPECT II & PROSPECT ABSORB Study: The Detection and Treatment of Vulnerable Plaques Co-Primary Investigator: David Erlinge, MD, PhD Co-Primary Investigator: Gregg W. Stone, MD

Presented at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation.

View Study Summary VIEW JACC ABSTRACT

Lipid Rich Plaque (LRP) Study: Assessment of Coronary Near-Infrared Spectroscopy Imaging to Detect Vulnerable Plaques and Vulnerable Patients Principal Investigator:Ron Waksman, MD View LRP Study Overview View The Lancet LRP Study

Near-Infrared Spectroscopy Predicts Cardiovascular Outcome in Patients with Coronary Artery Disease

Oemrawsingh RM, Cheng JM, García-García HM, et al

CONCLUSION:
CAD patients with an LCBI equal to or above the median of 43.0, as assessed by NIRS in a nonculprit coronary artery, had a 4-fold risk of adverse cardiovascular events during 1-year follow-up.

J Am Coll Cardiol. 2014 Dec 16;64(23):2510-8.

Large Lipid-Rich Coronary Plaques Detected by Near-Infrared Spectroscopy at Non-Stented Sites in the Target Artery Identify Patients Likely to Experience Future Major Adverse Cardiovascular Events

Madder RD, Husaini M, Davis AT, et al.

CONCLUSION:
NIRS-derived LCBI is associated with adverse cardiac outcome in CAD patients during long-term follow-up independent of clinical risk factors and plaque burden.

Eur Heart J Cardiovasc Imaging. 2016 Apr;17(4):393-9.

Near-Infrared Spectroscopy-Derived Lipid Core Burden Index Predicts Adverse Cardiovascular Outcome in Patients with Coronary Artery Disease During Long-Term Follow-Up

Schuurman A-S, Vroegindewey M, Kardys I, et al.

CONCLUSION:
Detection of large LRP by NIRS at non-stented sites in a target artery was associated with an increased risk of future MACCE.

Eur Heart J 2017; ehx247, Epub ahead of print.

Long-Term Follow-Up after Near-Infrared Spectroscopy Coronary Imaging: Insights From the Lipid Core Plaque Association with Clinical Events (ORACLE-NIRS) Registry

Danek BA, Karatasakis A, Karacsonyi J, et al.

CONCLUSION:
During long-term follow-up of patients who underwent NIRS imaging, high LCBI in a non-PCI target vessel was associated with increased incidence of MACE.

Cardiovasc Revascularization Med Mol Interv 2017;18(3):177–81.